This section contains the prescribed nomination forms used in nominating or applying for topics for HTA.
You may submit accomplished topic nomination forms or any of the documents listed above via our official email, htanominations@dost.gov.ph, during the designated timelines per HTA Track.
Note: The call for the 2023 HTA Topic nominations for Cycle 2 is already closed. The HTA Council will accept nominations only from the Department of Health (DOH) and Philippine Health Insurance Corporation (PhilHealth) in 2024, and open the Call for Nominations to other stakeholders in the 4th quarter of 2025 for Cycle 3.
Click here for more details.
The following is the latest HTA Topic Nomination and Prioritization Guidelines released in 31 August 2023.
The guidelines contain these 3 sections, namely: (1) Topic Nomination; (2) Topic Prioritization; and (3) Overall timelines for the Topic Nomination and Prioritization. You may access the guidelines through this link: 2023NomPrioGuidelines
You may download the Nomination forms from the file links in the table below:
| Name of Nomination Form | Downloadable Form |
| Clinical Equipment and Devices | ClinDevNomForm |
| Drugs and Vaccines | 2023DVNomForm |
| Medical and Surgical Procedures | 2023MedSPNomForm |
| Other Health Technologies | 2023OtherHTNomForm |
| Preventive and Promotive Health Services | 2023PrevPromNomForm |
| Traditional, Complementary and Integrative Medicine | 2023TradMedNomForm |
| Any Type of Health Technology for Patient Groups Civil/Society/Public | 2023PGCSONomForm |
We gently remind our stakeholders that HTA Philippines will not process incomplete or late submissions.
Per DOH Department Circular 2022-0254* and Department Circular 2022-0584*, the Minor inclusion track is applicable for drugs that are currently listed in the PNF, but are being applied for: change in or additional strength; packaging; net content; pack size/volume; and any other change that will not result in a significant difference in terms of bioavailability and meaningful clinical outcomes with the PNF-listed drugs.
This process track is open year-round and stakeholders may nominate/apply for drugs for minor inclusion given that they are already listed in the PNF. Kindly note, however, that all submissions shall be completed and submitted to the HTA Division within 14 working days after acknowledgement and validation of the requirements submitted. Please be advised that late and incomplete submissions will not be processed.
You may download the nomination form below:
* included in the guidelines to be updated in the DOST HTA AO.